AV
Anavex Life Sciences Corp.
AVXL · NASDAQ
$2.62 -3.32% (-$0.09)
1M -18.63%
Market Cap $264.1M
P/E Ratio -
Div. Yield -
ROE 11.96%
Bulios Fair Price
$1.93
26.3% downside
Current Price
$2.62
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AVXL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
83 /100
Cheap P/B 2.17x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 12.68%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 10.09%
ROIC 14.25%
Debt
100 /100
Low Current ratio 18.24x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
69 /100
Stable EPS volatility 8.63%
Profitable years 0
Beta 1.14x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AVXL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Terrie Kellmeyer
Employees
34
Headquarters
New York City
Upcoming events
24 NOV
Earnings
Upcoming earnings report